Skip to main content

Advertisement

SpringerLink
Log in

Hypertension-induced organ damage in african americans: Transforming growth factor-β1 excess as a mechanism for increased prevalence

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension is prevalent world-wide, and it affects over 50 million individuals in the United States alone. African Americans (blacks) have a high prevalence of hypertension, develop it at an earlier age, and suffer excessively from severe or malignant hypertension. They also have a high prevalence of target organ damage attributable to hypertension, including left ventricular hypertrophy, stroke, endstage renal disease (ESRD) and coronary artery disease. Hypertensive nephrosclerosis is particularly more prevalent in blacks compared to whites, and there is evidence that factors in addition to elevated blood pressure contribute to its pathogenesis. Transforming growth factor-beta 1 (TGF-β1) is a fibrogenic cytokine that has been implicated in the development and progression of experimental and human renal diseases. We have demonstrated that blacks with ESRD have higher circulating levels of TGF-β1 protein compared to whites with ESRD. We have also found that hyperexpression of TGF-b1 is more frequent in blacks with hypertension than in whites. We propose that TGF-β1 hyperexpression may be an important mediator of hypertension and hypertensive nephrosclerosis. We hypothesize also that the increased frequency of TGF-β1 hyperexpression may contribute to the excess burden of ESRD in blacks. Based on our hypotheses, and the observations that angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists reduce angiotensin II-mediated stimulation of TGF-β1 production, we propose that treatment with these agents might be efficacious in preventing or slowing the progression of target organ damage in hypertensive blacks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Burt Vl, Whelton P, Rocella EJ, et al.: Prevalence of hypertension in the US adult population: results of the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25:305–313.

    PubMed  CAS  Google Scholar 

  2. The Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure. The sixth report. Arch Intern Med 1997, 157:2413–2446.

  3. Lackland DT, Keil JE: Epidemiology of hypertension in African Americans. Semin Nephrol 1996, 16:63–70.

    PubMed  CAS  Google Scholar 

  4. Flack JM, Staffileno BA: Hypertension in blacks. In Hypertension: A Companion to Brenner and Rector’s The Kidney. Edited by Oparil S, Weber MA. Philadelphia: WB Saunders; 2000:558–563.

    Google Scholar 

  5. He J, Whelton PK What is the role of dietary sodium and potassium in hypertension and target organ injury? Am J Med Sci 1999, 317:152–159.

    Article  PubMed  CAS  Google Scholar 

  6. Ambrosius WT, Bloem LJ, Zhou L, et al.: Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension 1999, 34:631–637.

    PubMed  CAS  Google Scholar 

  7. Dong Y, Zhu H, Sagnella GA, et al.: Association between the C825T polymorphism of the G protein beta3-subunit gene and hypertension in blacks. Hypertension 1999, 34:1193–1196.

    PubMed  CAS  Google Scholar 

  8. Taylor JO, Borhani NO, Entwisle G: Summary of the baseline characteristics of the hypertensive participants. Hypertension 1983, 5[suppl 4]:44–50.

    Google Scholar 

  9. Rosamond WD, Folsom AR, Chambless LE, et al.: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999, 30:736–740. Demonstration that black patients have 38% greater risk of ischemic strokes compared to white patients.

    PubMed  CAS  Google Scholar 

  10. U.S. Renal Data System (USRDS) 1998 Annual Data Report. Bethesda: The National Institutes of Health & NIDDK; 1998. The report is a summary of data demonstrating that end-stage renal disease (ESRD) is four times more frequent in black patients compared to white patients. The report also demonstrates that ESRD attributable hypertension is 20 times more frequent in black patients compared to non-black patients.

  11. Klag MJ, Whelton PK, Randall BL, et al.: End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997, 277:1293–1298.

    Article  PubMed  CAS  Google Scholar 

  12. Klahr S: Prevention of progression of nephropathy. Nephrol Dial Transplant 1997, 12(suppl 2):63–66. Black race is shown to be a risk factor for renal disease progression in this multicenter, controlled interventional trial.

    PubMed  Google Scholar 

  13. Dooley MA, Hogan S, Jennette C, Falk R: Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997, 51:1188–1195.

    Article  PubMed  CAS  Google Scholar 

  14. Rostand SG, Brown G, Kirk KA, et al.: Renal insufficiency in treated essential hypertension. N Engl J Med 1989, 320:684–688.

    Article  PubMed  CAS  Google Scholar 

  15. Perry HM Jr, Miller JP, Fornoff JR, et al.: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995, 25:587–594.

    PubMed  Google Scholar 

  16. Freedman BI, Soucie JM, McClellan WM: Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 1997, 8:1942–1945. The above report emphasizes the high prevalence of kidney disease in family members of black end-stage renal disease.

    PubMed  CAS  Google Scholar 

  17. Bergman S, Key BO, Kirk KA, et al.: Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. Am J Kidney Dis 1996, 27:341–346. The above report emphasizes the high prevalence of kidney disease in family members of black end-stage renal disease.

    PubMed  CAS  Google Scholar 

  18. Roberts AM, Sporn MB: Transforming growth factor. Adv Cancer Res 1988, 51:107–145.

    PubMed  CAS  Google Scholar 

  19. Massagne J: The transforming growth factor family. Ann Rev Cell Dev Biol 1990, 6:597–641.

    Article  Google Scholar 

  20. Vilarreal FJ, Dillman WH: Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta, fibronectin and collagen. Am J Physiol 1992, 262:H1861-H1866.

    Google Scholar 

  21. Sarzani R, Brecher P, Chobanian AV: Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest 1989, 83:1404–1408.

    PubMed  CAS  Google Scholar 

  22. Ketteler M, Noble NA, Border WA: Increased expression of transforming growth factor beta in renal disease. Curr Opin Nephrol Hypertens 1994, 3:446–452.

    Article  PubMed  CAS  Google Scholar 

  23. Border WA, Noble NA: Interactions of transforming growth factor and angiotensin II in renal fibrosis. Hypertension 1998, 31:181–188. An excellent review of the implications of the regulatory interaction between transforming growth factor-b and angiotensin II.

    PubMed  CAS  Google Scholar 

  24. Isaka Y, Fujiwara Y, Ueda N, et al.: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993, 92:2597–2601.

    Article  PubMed  CAS  Google Scholar 

  25. Akagi Y, Isaka Y, Arai M, et al.: Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996, 50:148–155.

    Article  PubMed  CAS  Google Scholar 

  26. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522–530.

    Article  PubMed  CAS  Google Scholar 

  27. Bottinger EP, Letterio JJ, Roberts AB: Biology of TGF-beta 1 in knockout and transgenic mouse models. Kidney Int 1997, 51:1255–1360.

    Article  Google Scholar 

  28. Yamamoto T, Noble NA, Cohen AH, et al.: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49:461–469.

    Article  PubMed  CAS  Google Scholar 

  29. Iwano M, Kubo A, Nishino T, et al.: Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 1996, 49:1120–1126.

    Article  PubMed  CAS  Google Scholar 

  30. Sharma VK, Bologa RM, Xu G-P, et al.: Intragraft TGF-β1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996, 49:1297–1303.

    Article  PubMed  CAS  Google Scholar 

  31. Suthanthiran M, Khanna A, Cukran D, et al.: Transforming growth factor B1 hyperexpression in African American endstage renal disease patients. Kidney Int 1998, 53:639–644. This is the first report of transforming growth factor b1 protein excess in black end-stage renal disease (ESRD) patients compared to white ESRD patients.

    Article  PubMed  CAS  Google Scholar 

  32. Li B, Khanna A, Sharma V, et al.: TGF-1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999, 33:271–275. This is the first analysis of transforming growth factor b1 (TGF-β1) DNA polymorphisms in blacks and whites, and determination of the correlation between TGF-b1 protein levels and blood pressure.

    PubMed  CAS  Google Scholar 

  33. Suthanthiran M, Li B, Song JO, et al.: TGF-β1 Hyperexpression in African American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000, in press.

  34. Ergul S, Parish DC, Puett D, Ergul A: Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996, 28:652–655.

    PubMed  CAS  Google Scholar 

  35. Kurihara H, Yoshizumi M, Sugiyama T, et al.: Transforming growth factor β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989, 159:1435–1440.

    Article  PubMed  CAS  Google Scholar 

  36. Antonipillai I, Hoang Le T, Soceneantu L, Horton R: Transforming growth factor is a renin secretagogue at picomolar concentrations. Am J Physiol 1993, 265:F537-F541.

    PubMed  CAS  Google Scholar 

  37. Nabel EG, Shum L, Pompili VJ, et al.: Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A 1993, 90:10759–10763. Demonstration of a cause and effect relationship between transforming growth factor β1 expression and induction of fibrocellular hyperplasia.

    Article  PubMed  CAS  Google Scholar 

  38. Saltis J, Agrotis A, Bobil A: Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Clin Exp Pharmacol Physiol 1996, 23:193–200.

    PubMed  CAS  Google Scholar 

  39. Agrotis A, Saltis J, Bobik A: Effect of transforming growth factor beta 1 on platelet-derived growth factor receptor binding and gene expression in vascular smooth muscle cells from SHR and WKY rats. Clin Exp Pharmacol Physiol 1994, 21:145–148.

    PubMed  CAS  Google Scholar 

  40. Cambien F, Ricard S, Troesch A, et al.: Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l’Infarctus du Myocarde (ECTIM) Study. Hypertension 1996, 28:881–887. This is the first description of seven DNA polymorphisms in the human transforming growth factor b1 gene and the correlation between the biallelic polymorphisms at codon 25 and blood pressure levels/history.

    PubMed  CAS  Google Scholar 

  41. Awad MR, El-Gamel A, Hasleton P, et al.: Genotypic variation in the transforming growth factor beta-1 gene: association with TGF-β1 production, fibrotic lung disease and graft fibrosis after lung transplantation. Transplantation 1998, 66:1014–1020.

    Article  PubMed  CAS  Google Scholar 

  42. Chapman JN, Mayet J, Chang CL, et al.: Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. Am J Hypertens 1999, 12:437–442.

    Article  PubMed  CAS  Google Scholar 

  43. Olutade BO, Gbadebo TD, Porter VD, et al.: Racial differences in ambulatory blood pressure and echocardiographic left ventricular geometry. Am J Med Sci 1998, 315:101–109.

    Article  PubMed  CAS  Google Scholar 

  44. Arnett DK, Rautaharju P, Crow R, et al.: Black-white differences in electrocardiographic left ventricular mass and its association with blood pressure (the Atherosclerosis Risk in Communities study). Am J Cardiol 1994, 74:247–252.

    Article  PubMed  CAS  Google Scholar 

  45. Flack JM, Gardin JM, Yunis C, Liu K: Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: The CARDIA study. Am Heart J 1999, 138:856–864.

    Article  PubMed  CAS  Google Scholar 

  46. Mayet J, Chapman M, Li CK, et al.: Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. Hypertension 1998, 31:1190–1194.

    PubMed  CAS  Google Scholar 

  47. Porreca E, Di Febbo C, Mincione G, et al.: Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997, 30:134–139.

    PubMed  CAS  Google Scholar 

  48. Williams JE, Massing M, Rosamond WD: Racial disparities in CHD mortality from 1968–1992 in the state economic areas surrounding the ARIC study communities. Atherosclerosis Risk in Communities. Ann Epidemiol 1999, 9:472–480.

    Article  PubMed  CAS  Google Scholar 

  49. Barnett E, Armstrong DL, Casper ML. Evidence of increasing coronary heart disease mortality among black men of lower social class. Ann Epidemiol 1999, 9:464–471.

    Article  PubMed  CAS  Google Scholar 

  50. Taylor HA Jr, Mickel MC, Chaitman BR, et al.: Long-term survival of African Americans in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1997, 29:358–364.

    Article  PubMed  Google Scholar 

  51. Qureshi AI, Suri MAK, Safdar K, et al.: Intracerebral hemorrhage in blacks. Risk factors, subtypes, and outcome. Stroke 1997, 28:961–964.

    PubMed  CAS  Google Scholar 

  52. HallWD, Ferrario CM, Moore MA, et al.: Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 1997, 313:195–209.

    Article  Google Scholar 

  53. Sacco RL, Roberts JK, Boden-Albala B, et al.: Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population. The Northern Manhattan Stroke Study. Stroke 1997, 28:929–935.

    PubMed  CAS  Google Scholar 

  54. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of Hypertension Detection and Follow-up Program II: Mortality by race-sex and age. JAMA 1979, 242:2572–2576.

    Article  Google Scholar 

  55. Bianchi S, Bigassi R, Baldari G, et al.: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994, 7:23–29.

    PubMed  CAS  Google Scholar 

  56. Timio M, Venanzi S, Lolli S, et al.: "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 1995, 43:382–387.

    PubMed  CAS  Google Scholar 

  57. Tomita H, Egashira K, Ohara Y, et al.: Early induction of transforming growth factor-B via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998, 32:273–280.

    PubMed  CAS  Google Scholar 

  58. Rumble JR, Gilbert RE, Cox A, et al.: Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. J Hypertens 1998, 16:1603–1609.

    Article  PubMed  CAS  Google Scholar 

  59. Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54:1570–1580. An editorial advancing the idea that angiotensin II blockade can prevent renal damage due to transforming growth factor-b1 excess.

    Article  PubMed  CAS  Google Scholar 

  60. Campistol JM, Inigo P, Jinenez W, et al.: Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56:714–719. This clinical trial study shows that angiotensin II blockade results in the reduction of circulating levels of transforming growth factor-β1 and that this reaction might be renoprotective.

    Article  PubMed  CAS  Google Scholar 

  61. Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34:818–823. This clinical trial study shows that angiotensin II blockade results in the reduction of circulating levels of transforming growth factor-β1 and that this reaction might be renoprotective.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Nephrology and Hypertension, Weill Medical College of Cornell University, 525 East 68th Street, 10021, New York, NY, USA

    Phyllis August MD, Beth Leventhal MD & Manikkam Suthanthiran MD

Authors
  1. Phyllis August MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beth Leventhal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manikkam Suthanthiran MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

August, P., Leventhal, B. & Suthanthiran, M. Hypertension-induced organ damage in african americans: Transforming growth factor-β1 excess as a mechanism for increased prevalence. Current Science Inc 2, 184–191 (2000). https://doi.org/10.1007/s11906-000-0080-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-000-0080-5

Keywords

Search

Navigation